Latest & greatest articles for fluticasone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fluticasone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fluticasone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fluticasone

81. Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs

Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs O'Connor R D (...) , Stanford R, Crim C, Yancey S W, Edwards L, Rickard K A, Dorinsky P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of three alternative first-line maintenance treatments for asthma control: fluticasone propionate (100 microg

2004 NHS Economic Evaluation Database.

82. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma

Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma O'Connor R D, Nelson H, Borker R, Emmett A, Jhingran P (...) , Rickard K, Dorinsky P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two combination treatments for patients with persistent asthma were examined. One was fluticasone propionate (FP) 100 microg and salmeterol (SAL) 50 microg

2004 NHS Economic Evaluation Database.

83. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. (PubMed)

Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. To explore the efficacy and safety of fluticasone propionate, cream and ointment, applied twice weekly in addition to maintenance treatment with emollients, in reducing the risk of relapse of chronic recurrent atopic dermatitis.Randomised, double blind, parallel group study of 20 weeks' duration.Dermatology outpatient (...) clinics (6 countries, 39 centres).Adult (aged 12-65) patients with moderate to severe atopic dermatitis who were experiencing a flare.Participants applied fluticasone propionate (0.05% cream or 0.005% ointment; once or twice daily) regularly for four weeks to stabilise their condition. The patients whose disease was brought under control then continued into a 16 week maintenance phase, applying emollient on a daily basis with a bath oil as needed and either the same formulation of fluticasone

Full Text available with Trip Pro

2003 BMJ

84. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. (PubMed)

Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. To assess the effect of montelukast versus salmeterol added to inhaled fluticasone propionate on asthma exacerbation in patients whose symptoms are inadequately controlled with fluticasone alone. Design and setting A 52 week, two period, double blind, multicentre trial during which patients whose symptoms remained (...) uncontrolled by inhaled corticosteroids were randomised to add montelukast or salmeterol.Patients (15-72 years; n = 1490) had a clinical history of chronic asthma for > or = 1 year, a baseline forced expiratory volume in one second (FEV1) value 50-90% predicted, and a beta agonist improvement of > or = 12% in FEV1.The primary end point was the percentage of patients with at least one asthma exacerbation.20.1% of the patients in the group receiving montelukast and fluticasone had an asthma exacerbation

Full Text available with Trip Pro

2003 BMJ

85. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. (PubMed)

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Inhaled long-acting beta2 agonists improve lung function and health status in symptomatic chronic obstructive pulmonary disease (COPD), whereas inhaled corticosteroids reduce the frequency of acute episodes of symptom exacerbation and delay deterioration in health status. We postulated that a combination of these treatments would be better than each component used alone (...) .1465 patients with COPD were recruited from outpatient departments in 25 countries. They were treated in a randomised, double-blind, parallel-group, placebo-controlled study with either 50 microg salmeterol twice daily (n=372), 500 microg fluticasone twice daily (n=374), 50 microg salmeterol and 500 microg fluticasone twice daily (n=358), or placebo (n=361) for 12 months. The primary outcome was the pretreatment forced expiratory volume in 1s (FEV1) after 12 months treatment' and after patients had

2003 Lancet

86. Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial

Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial Ayres J G, Price M J, Efthimiou (...) J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of fluticasone propionate (FP; 2 puffs of 250 microg twice daily), added to regular bronchodilator therapy for the treatment of chronic obstructive pulmonary disease

2003 NHS Economic Evaluation Database.

87. Use of salmeterol/fluticasone combination (seretide) in an asthma clinic: a pragmatic open study from primary care

Use of salmeterol/fluticasone combination (seretide) in an asthma clinic: a pragmatic open study from primary care Use of salmeterol/fluticasone combination (seretide) in an asthma clinic: a pragmatic open study from primary care Use of salmeterol/fluticasone combination (seretide) in an asthma clinic: a pragmatic open study from primary care Clark C E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of a salmeterol-fluticasone combination (Seretide) inhaler for treating asthma. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients with asthma who attended a nurse-run asthma clinic in a rural dispensing general practice. Patients

2003 NHS Economic Evaluation Database.

88. Fluticasone versus beclomethasone or budesonide for chronic asthma. (PubMed)

Fluticasone versus beclomethasone or budesonide for chronic asthma. Beclomethasone dipropionate (BDP) and budesonide (BUD) are commonly prescribed inhaled corticosteroids for the treatment of asthma, Fluticasone propionate (FP) is newer agent with greater potency in in-vitro assays.To compare the efficacy and safety of Fluticasone to Beclomethasone or Budesonide in the treatment of chronic asthma.We searched the Cochrane Airways Group Trial Register (1999) and reference lists of articles. We (...) contacted trialists and pharmaceutical companies for additional studies and searched abstracts of major respiratory society meetings (1997-1999).Randomised trials in children and adults comparing Fluticasone to either Beclomethasone or Budesonide in the treatment of chronic asthma. Two reviewers independently assessed articles for inclusion and methodological quality.One reviewer extracted data. Quantitative analyses where undertaken using Review Manager 4.0.3 with Metaview 3.1.42 studies (>10,000

2002 Cochrane

89. Inhaled fluticasone at different doses for chronic asthma. (PubMed)

Inhaled fluticasone at different doses for chronic asthma. Inhaled fluticasone propionate (FP) is a high potency inhaled corticosteroid used in the treatment of asthma.1. To assess the efficacy and safety outcomes in studies that compared inhaled fluticasone at different nominal daily doses in the treatment of chronic asthma. 2. To test for the presence of a dose response effect.We searched the Cochrane Airways Group Trial Register (1999) and reference lists of articles. We contacted trialists (...) and pharmaceutical companies for additional studies and searched abstracts of major respiratory society meetings (1997-1999).Randomised trials in children and adults comparing fluticasone at different nominal daily doses in the treatment of chronic asthma. Two reviewers independently assessed articles for inclusion and methodological quality.One reviewer extracted data. Quantitative analyses where undertaken using Review Manager 4.0.3 with Metaview 3.1.20 studies (>6000 patients) met the inclusion criteria

2002 Cochrane

90. Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population

Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population Pathak D S, Davis E A, Stanford R H Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health technology was controller therapy for patients with asthma. The comparators were inhaled corticosteroids and leukotriene modifiers in real world clinical practice. The authors compared fluticasone propionate (44 or 110 microg) with oral zafirlukast (20 mg) and montelukast

2002 NHS Economic Evaluation Database.

91. Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma

Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma Sheth K, Borker R, Emmett A, Rickard K, Dorinsky P Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two initial maintenance treatments for patients with persistent asthma were examined. Salmeterol-fluticasone propionate (SF; salmeterol 50 microg and fluticasone propionate 100 microg) delivered twice daily via

2002 NHS Economic Evaluation Database.

92. Comparison of cefuroxime with or without intranasal fluticasone for the treatment of rhinosinusitis. The CAFFS Trial: a randomized controlled trial. (PubMed)

Comparison of cefuroxime with or without intranasal fluticasone for the treatment of rhinosinusitis. The CAFFS Trial: a randomized controlled trial. It is not known whether intranasal corticosteroids are beneficial to treat acute rhinosinusitis in patients with a history of chronic or recurrent sinus symptoms.To assess whether the addition of an intranasal corticosteroid to antibiotic therapy affects the speed and rate of recovery of such patients with acute rhinosinusitis.A double-blind (...) , randomized, placebo-controlled multicenter trial of 95 patients (median age, 39 years) with a history of recurrent sinusitis or chronic rhinitis and evidence of acute infection by sinus radiograph or nasal endoscopy, which was conducted from October 1998 through April 2000 at 22 sites (12 primary care and 10 otolaryngology).Two puffs (total dose, 200 microgram) of fluticasone propionate (n = 47) or placebo nasal spray (n = 48) in each nostril once daily for 21 days; all received 2 puffs of xylometazoline

2001 JAMA

93. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. (PubMed)

Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. To examine the dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma.Meta-analysis of placebo controlled, randomised clinical trials that presented data on at least one outcome measure of asthma and that used at least two different doses of fluticasone.Medline, Embase, and GlaxoWellcome's internal clinical study registers.FEV(1), morning (...) ).In adolescent and adult patients with asthma, most of the therapeutic benefit of inhaled fluticasone is achieved with a total daily dose of 100-250 microg, and the maximum effect is achieved with a dose of around 500 microg/day. However, these findings were limited by the lack of data on individual patients and by the paucity of dose-response studies that included doses of >500 microg/day.

Full Text available with Trip Pro

2001 BMJ

94. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis

Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R Authors' objectives To examine the dose-response relation of inhaled fluticasone propionate (...) in adolescents and adults with asthma. Searching MEDLINE was searched from January 1 1966 to December 1999 with the keyword 'fluticasone'. This search was combined with a search using the MeSH terms 'asthma' and 'chemical and pharmacologic phenomena' or 'dose-response relationship, drug', or the keywords 'dose' or 'dosage'. EMBASE was searched from 1980 to December 1999 using the keywords 'fluticasone' and 'dose' or 'dosage'. Additional studies were identified by contacting the manufacturer of fluticasone

2001 DARE.

95. One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma

One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma Stempel D A, Meyer J W, Stanford R H, Yancey S W Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health technology under investigation was the use of inhaled corticosteroids (ICSs), specifically fluticasone propionate (FP), in the treatment of asthma. Type of intervention Treatment and secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study

2001 NHS Economic Evaluation Database.

96. Cost-effectiveness of fluticasone propionate administered via metered-dose inhaler plus Babyhaler spacer in the treatment of asthma in preschool-aged children

Cost-effectiveness of fluticasone propionate administered via metered-dose inhaler plus Babyhaler spacer in the treatment of asthma in preschool-aged children Cost-effectiveness of fluticasone propionate administered via metered-dose inhaler plus Babyhaler spacer in the treatment of asthma in preschool-aged children Cost-effectiveness of fluticasone propionate administered via metered-dose inhaler plus Babyhaler spacer in the treatment of asthma in preschool-aged children Bisgaard H, Price M J (...) , Maden C, Olsen N A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined fluticasone propionate (FP), administered by a metered-dose inhaler and a Babyhaler spacer device. Type of intervention Secondary prevention

2001 NHS Economic Evaluation Database.

97. Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma

Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma Menendez R, Stanford R H, Edwards L, Kalberg C, Rickard K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two drug therapies were compared for the treatment of patients suffering from persistent asthma. The first was an inhaled glucocorticoid, fluticasone propionate (FP), at a dose of 88 microg twice daily. The second was a leukotriene receptor antagonist, zafirlukast (ZA), at a dose of 20 mg twice daily. Salbutamol

2001 NHS Economic Evaluation Database.

98. A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma. (PubMed)

A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma. Inhaled corticosteroids are effective in the treatment of children with asthma. It is uncertain how inhaled corticosteroids compare with oral corticosteroids in the management of severe acute disease.We performed a double-blind, randomized trial involving 100 children five years of age or older who had severe acute asthma (indicated by a forced expiratory volume in one second [FEV1] that was less than (...) 60 percent of the predicted value) and in whom the results could be evaluated. All were treated with an aggressive bronchodilator regimen and received one dose of either 2 mg of inhaled fluticasone through a metered-dose inhaler with a spacer or 2 mg of oral prednisone per kilogram of body weight. They were assessed hourly for up to four hours.The mean (+/-SD) base-line FEV1 as a percentage of the predicted value was 46.3+/-12.5 in the fluticasone group (51 subjects) and 43.9+/-9.9

2000 NEJM

99. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. (PubMed)

Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Inhaled corticosteroids are currently the cornerstone of asthma treatment. Some studies of high-dose fluticasone propionate in patients with no or mild asthma have, however, suggested substantial systemic absorption. We investigated the pharmacokinetics of fluticasone propionate in patients with asthma receiving appropriate doses (...) for severity.We did a double-blind, randomised, crossover study in 11 patients with asthma and 13 matched healthy controls (age 20-65 years; asthma patients forced expiratory volume in 1 s <75% and stable on high-dose inhaled corticosteroids). Patients received one 1000 microg intravenous dose or 1000 microg daily for 7 days inhaled (via spacer device) fluticasone propionate. In the 12 h after dosing, we monitored plasma fluticasone propionate and cortisol concentrations by mass spectrometry and competitive

2000 Lancet

100. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. (PubMed)

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. To determine the effect of long term inhaled corticosteroids on lung function, exacerbations, and health status in patients with moderate to severe chronic obstructive pulmonary disease.Double blind, placebo controlled study.Eighteen UK hospitals.751 men and women aged between 40 and 75 years with mean forced expiratory volume (...) in one second (FEV(1)) 50% of predicted normal.Inhaled fluticasone propionate 500 microgram twice daily from a metered dose inhaler or identical placebo.Efficacy measures: rate of decline in FEV(1) after the bronchodilator and in health status, frequency of exacerbations, respiratory withdrawals. Safety measures: morning serum cortisol concentration, incidence of adverse events.There was no significant difference in the annual rate of decline in FEV(1 )(P=0.16). Mean FEV(1) after bronchodilator

Full Text available with Trip Pro

2000 BMJ